Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis

被引:17
作者
Forbes, A
Al-Damluji, A
Ashworth, S
Bramble, M
Herbert, K
Ho, J
Kang, JY
Przemioslo, R
Shetty, A
机构
[1] St Marks Hosp, Harrow HA1 3UJ, Middx, England
[2] Sandoz Ltd, Bordon, Hants, England
[3] James Cook Univ Hosp, Middlesbrough, Cleveland, England
[4] Univ London St Georges Hosp, London, England
[5] Frenchay Hosp, Bristol BS16 1LE, Avon, England
关键词
D O I
10.1111/j.1365-2036.2005.02442.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: 5-Aminosalicylates remain important in the treatment of ulcerative colitis, but it is uncertain if the various preparations currently available are equivalent given the different delivery systems that exist. Generic prescription of mesalazine (mesalamine) is therefore inappropriate. Ipocol has recently become available as an alternative to Asacol-MR. Aim: To compare the two agents in a controlled trial using a non-inferiority design. Methods: Eighty-eight ulcerative colitis patients with a mild to moderate clinical relapse were randomized to one of the two drugs at a daily dose of 2.4 g for 8 weeks. Safety was the key concern; the primary measured end-point was efficacy as judged from a colitis activity index. Results: There were no unexpected adverse events of clinical consequence. The colitis score improved similarly in both patient groups (by 2.3 with Ipocol and by 1.5 with Asacol: not significant), and a similar proportion was in clinical remission at the end of the study (26.1% for Ipocol and 28.6% for Asacol: not significant). Systemic steroids were needed in 11.9% of the Asacol-treated patients compared with 6.5% with Ipocol (not significant). Conclusion: It appears appropriate to conclude that, while not identical to Asacol-MR, Ipocol offers a safe and similarly effective alternative.
引用
收藏
页码:1099 / 1104
页数:6
相关论文
共 8 条
[1]  
[Anonymous], ICH HARM TRIP GUID C
[2]   Review article: oral, modified-release mesalazine formulations - proprietary versus generic [J].
Forbes, A ;
Cartwright, A ;
Marchant, S ;
McIntyre, P ;
Newton, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (10) :1207-1214
[3]  
FORBES A, 2001, INFLAMMATORY BOWEL D
[4]   Comparison of the EQ-5D and SF-12 in an adult US sample [J].
Johnson, JA ;
Coons, SJ .
QUALITY OF LIFE RESEARCH, 1998, 7 (02) :155-166
[5]   Trials to assess equivalence: The importance of rigorous methods [J].
Jones, E ;
Jarvis, P ;
Lewis, JA ;
Ebbutt, AF .
BMJ-BRITISH MEDICAL JOURNAL, 1996, 313 (7048) :36-39
[6]  
PEPPERCORN MA, 1973, GASTROENTEROLOGY, V64, P240
[7]   CORRELATIONS BETWEEN DEFINED SIGMOIDOSCOPIC APPEARANCES AND OTHER MEASURES OF DISEASE-ACTIVITY IN ULCERATIVE-COLITIS [J].
POWELLTUCK, J ;
DAY, DW ;
BUCKELL, NA ;
WADSWORTH, J ;
LENNARDJONES, JE .
DIGESTIVE DISEASES AND SCIENCES, 1982, 27 (06) :533-537
[8]   Oral delayed-release mesalazine - A review of its use in ulcerative colitis and Crohn's disease [J].
Prakash, A ;
Markham, A .
DRUGS, 1999, 57 (03) :383-408